TCGA-IQ-A61E-01A-22R-A30B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.590
- INTERFERON_ALPHA_RESPONSE+0.580
- MYC_TARGETS_V1+0.570
- G2M_CHECKPOINT+0.530
- MYC_TARGETS_V2+0.490
- INTERFERON_GAMMA_RESPONSE+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- DNA_REPAIR+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.360
- TNFA_SIGNALING_VIA_NFKB+0.350
Top 10 suppressed
- BILE_ACID_METABOLISM-0.190
- ESTROGEN_RESPONSE_EARLY-0.190
- KRAS_SIGNALING_DN-0.180
- HEDGEHOG_SIGNALING-0.150
- FATTY_ACID_METABOLISM-0.130
- HEME_METABOLISM-0.080
- WNT_BETA_CATENIN_SIGNALING-0.060
- APICAL_SURFACE-0.040
- PEROXISOME-0.030
- ADIPOGENESIS-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | fca4c327-dfab-4455-84a8-f890a7326132 | — | — | 0.917 |
| 2 | 91E04630-B2A7-448E-8C80-580818C9D7E6 | — | — | 0.904 |
| 3 | 6B8CAF74-45C6-4C20-8126-A99F73346198 | — | — | 0.900 |
| 4 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.891 |
| 5 | TCGA-UY-A8OB-01A-12R-A42T-07 | — | — | 0.888 |
| 6 | E92DD0CC-DD0F-469D-8357-228A4A67DBD6 | — | — | 0.888 |
| 7 | D1729A17-148B-4C58-BEB5-7C4349A0E920 | — | — | 0.887 |
| 8 | SRR1516056 | — | — | 0.886 |
| 9 | SRR12696771 | — | — | 0.884 |
| 10 | SRR934839 | — | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.580 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| HYPOXIA | 0.250 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |